Compare Amphastar Pharmaceuticals Inc (AMPH) vs Orion Office REIT Inc (ONL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Orion Office REIT Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Orion Office REIT Inc trades at $2.78 (market cap $156.87M). The key difference: Amphastar Pharmaceuticals Inc is far larger — about 5.5× Orion Office REIT Inc's market cap, and Orion Office REIT Inc pays a 2.91% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | ONL | |
|---|---|---|
Market Cap | $863.95M | $156.87M |
Sector | Health | Real Estate |
52-Week High | $30.81 | $3.04 |
52-Week Low | $16.87 | $1.93 |
Enterprise Value | $1.26B | $573.80M |
Dividend Yield | — | 2.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
ONL trades at $2.82, up 8.46% today, with strong technical indicators showing bullish momentum. The stock shows mixed fundamentals with a low P/B ratio of 0.25 but negative profitability metrics including -65.66% net income margin. Recent Q2 2026 earnings beat expectations with EPS of $0.42 versus -$0.07 forecast, while the company continues strategic portfolio repositioning and maintains a $0.02 dividend payment.
Outlook remains cautious due to persistent net losses and declining revenue trends, though analyst consensus is evenly split between Buy and Hold ratings. Key risks include high debt levels with 39.68% debt-to-asset ratio and ongoing negative cash flow from operations. The technical bullish signal suggests short-term upside potential despite fundamental challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →
